Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other financing activities: 2009-2025

Historic Other financing activities for Gyre Therapeutics (GYRE) over the last 4 years, with Sep 2025 value amounting to -$315,000.

  • Gyre Therapeutics' Other financing activities fell 730.00% to -$315,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 75.66%. This contributed to the annual value of $536,000 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Gyre Therapeutics' Other financing activities stood at -$315,000, which was down 118.74% from $1.7 million recorded in Q2 2025.
  • Gyre Therapeutics' Other financing activities' 5-year high stood at $1.7 million during Q2 2025, with a 5-year trough of -$315,000 in Q3 2025.
  • Its 2-year average for Other financing activities is $380,800, with a median of $121,000 in 2025.
  • Data for Gyre Therapeutics' Other financing activities shows a maximum YoY tumbled of 730.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Gyre Therapeutics' Other financing activities stood at $367,000 in 2024, then tumbled by 730.00% to -$315,000 in 2025.
  • Its Other financing activities stands at -$315,000 for Q3 2025, versus $1.7 million for Q2 2025 and $121,000 for Q1 2025.